EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Coherus Oncology, Inc. (CHRS) had EBIT Margin of -41.83% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$266.96M |
|
$28.51M |
|
$117.55M |
|
$149.41M |
|
$378.63M |
|
$-111.67M |
|
$140.17M |
|
$28.51M |
|
$28.51M |
|
$28.51M |
|
$28.51M |
|
$28.51M |
|
$28.51M |
|
$-111.67M |
|
$-106.39M |
|
114.55M |
|
114.83M |
|
$0.25 |
|
$0.25 |
|
| Balance Sheet Financials | |
$341.58M |
|
$2.84M |
|
$106.95M |
|
$448.53M |
|
$282.98M |
|
$264.93M |
|
$297.54M |
|
$580.52M |
|
$-131.99M |
|
$-185.64M |
|
$-131.99M |
|
115.61M |
|
| Cash Flow Statement Financials | |
$-20.44M |
|
$230.32M |
|
$-186.97M |
|
$103.34M |
|
$126.25M |
|
$22.91M |
|
$27.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.21 |
|
-- |
|
-- |
|
1.99 |
|
-2.01 |
|
55.97% |
|
-41.83% |
|
|
EBIT Margin |
-41.83% |
-39.85% |
|
10.68% |
|
10.68% |
|
$-20.44M |
|
-- |
|
-- |
|
-- |
|
0.60 |
|
1.68 |
|
2.18 |
|
167.26 |
|
-21.60% |
|
-15.36% |
|
6.36% |
|
21.44% |
|
$-1.14 |
|
$-0.18 |
|
$-0.18 |
|